Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929677 | 0.99 | LTB4R (0.47) | BRD4LTB4RLTB4R2S1PR5PLA2G4B | |
| SCHEMBL4450768 | 0.87 | LTB4R (0.49) | BRD4LTB4RLTB4R2TSHR | |
| SCHEMBL13956434 | 0.87 | LTB4R (0.47) | BRD4LTB4RLTB4R2TSHR | |
| SCHEMBL4453277 | 0.87 | LTB4R (0.47) | BRD4LTB4RLTB4R2TSHR | |
| SCHEMBL13971111 | 0.86 | LTB4R (0.44) | BRD4LTB4RLTB4R2TSHR | |
| SCHEMBL11811840 | 0.85 | BRD4 (0.46) | BRD4 | |
| SCHEMBL13956436 | 0.84 | BRD4 (0.40) | BRD4LTB4RLTB4R2S1PR5TSHR | |
| SCHEMBL2926371 | 0.83 | BRD4 (0.38) | BRD4LTB4RLTB4R2 | |
| SCHEMBL2929875 | 0.81 | PTGDR2 (0.44) | BRD4S1PR5TSHRMEN1ALOX15 | |
| SCHEMBL2932345 | 0.81 | S1PR5 (0.45) | BRD4S1PR5TSHRMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | claimed |
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | MERCK PATENT GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| EP-1836150-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | Merck Patent GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006074798-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-07-20 | — | — | WO | claimed |
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | MERCK PATENT GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1836150-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | Merck Patent GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006074798-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | PPARG, PPARA, PPARD | BRD4 676/4885LTB4R 231/4885LTB4R2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.